Awaiting IPO, CardioDx Raises $21M in Private Financing | GenomeWeb

NEW YORK (GenomeWeb) – Cardiovascular molecular diagnostics company CardioDx has raised $21 million toward a targeted goal of $25 million, it disclosed in a regulatory document filed on Wednesday.

A company spokesperson told GenomeWeb Daily News that the firm is "not commenting on its financing activities at this time."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.